
### [MONDO:0018904](http://purl.obolibrary.org/obo/MONDO_0018904)
**Label:** primary membranoproliferative glomerulonephritis

**Subclasses:** [MONDO:0013892](http://purl.obolibrary.org/obo/MONDO_0013892) (C3 glomerulonephritis), [MONDO:0012350](http://purl.obolibrary.org/obo/MONDO_0012350) (complement factor H deficiency), [MONDO:0019736](http://purl.obolibrary.org/obo/MONDO_0019736) (dense deposit disease), [MONDO:0014005](http://purl.obolibrary.org/obo/MONDO_0014005) (immunoglobulin-mediated membranoproliferative glomerulonephritis), [MONDO:0018159](http://purl.obolibrary.org/obo/MONDO_0018159) (atypical hemolytic-uremic syndrome with DGKE deficiency), [MONDO:0018013](http://purl.obolibrary.org/obo/MONDO_0018013) (non-immunoglobulin-mediated membranoproliferative glomerulonephritis), [MONDO:0010596](http://purl.obolibrary.org/obo/MONDO_0010596) (membranoproliferative glomerulonephritis, X-linked), [MONDO:0016061](http://purl.obolibrary.org/obo/MONDO_0016061) (immunodeficiency with factor H anomaly), [MONDO:0019738](http://purl.obolibrary.org/obo/MONDO_0019738) (atypical hemolytic-uremic syndrome with H factor anomaly), 

**Mapped go classes:** [GO:0008150](http://purl.obolibrary.org/obo/GO_0008150) (biological_process), [GO:0008152](http://purl.obolibrary.org/obo/GO_0008152) (metabolic process), [GO:0004143](http://purl.obolibrary.org/obo/GO_0004143) (diacylglycerol kinase activity), [GO:0007205](http://purl.obolibrary.org/obo/GO_0007205) (protein kinase C-activating G-protein coupled receptor signaling pathway), [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component), [GO:0003674](http://purl.obolibrary.org/obo/GO_0003674) (molecular_function), [GO:0046834](http://purl.obolibrary.org/obo/GO_0046834) (lipid phosphorylation), [GO:0003951](http://purl.obolibrary.org/obo/GO_0003951) (NAD+ kinase activity), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0016310](http://purl.obolibrary.org/obo/GO_0016310) (phosphorylation), [GO:0016740](http://purl.obolibrary.org/obo/GO_0016740) (transferase activity), [GO:0016301](http://purl.obolibrary.org/obo/GO_0016301) (kinase activity), [GO:0035556](http://purl.obolibrary.org/obo/GO_0035556) (intracellular signal transduction), 

**Class expressions from DL-Learner:**

- [GO:0007205](http://purl.obolibrary.org/obo/GO_0007205) (protein kinase C-activating G-protein coupled receptor signaling pathway) 62.50%
- [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding) 62.50%
- [GO:0004143](http://purl.obolibrary.org/obo/GO_0004143) (diacylglycerol kinase activity) 62.50%
- [GO:0003951](http://purl.obolibrary.org/obo/GO_0003951) (NAD+ kinase activity) 62.50%
- [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 62.50%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0036094](http://purl.obolibrary.org/obo/GO_0036094) (small molecule binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 62.50%


